匹伐他汀联合胺碘酮对阵发性房颤患者的疗效

Therapeutic effect of pitavastatin combined with amiodarone in patients with paroxysmal atrial fibrillation

目的观察口服匹伐他汀联合胺碘酮对阵发性房颤患者窦性心律的维持及左房内径、C反应蛋白的影响。方法 120例阵发性房颤患者,随机分为对照组(胺碘酮组)和试验组(匹伐他汀+胺碘酮组),每组60例,疗程为6月。观察治疗前和治疗6月后窦性心律维持率、左心房内径、血脂、血清高敏C反应蛋白(hs-CRP)的变化。结果治疗6月后,试验组窦性心律的维持率比对照组明显升高(P<0.05);试验组左心房内径较对照组明显减小;治疗6月后,试验组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和三酰甘油(TG)以及hs-CRP水平较治疗前均明显降低(P<0.05),与对照组比较有显著差异(P<0.05)。结论匹伐他汀可能通过抑制炎症反应,改善左心房的重构,有助于阵发性房颤患者窦性心律的维持,且其作用可能与其调脂作用有关。

Objective To observe the therapeutic effect of oral pitavastatin combined with amiodarone in patients with paroxysmal atrial fibrillation according to its performance in maintaining sinus rhythm and impacts on left atrial diameter （LAD） and C-reactive protein （CRP） level. Methods A total of 120 patients with paroxysmal atrial fibrillation were randomly divided into control group （n=60） and experimental group （n=60） to receive amiodarone and pitavastatin plus amiodarone, respectively. The course of treatment was 6 months. After 6 months of treatment, the changes in maintenance rate of sinus rhythm, LAD, blood lipid, and serum high-sensitivity CRP （hs-CRP） level were observed. Results After 6 months of treatment, the experimental group had a significantly higher maintenance rate of sinus rhythm and a significantly smaller LAD than the control group （P〈0.05）; the experimental group showed significant decreases in total cholesterol, low-density lipoprotein cholesterol, triglyceride, and hs-CRP levels after the 6-month treatment （P〈0.05）, and there were significant differences in these indices between the experimental group and control group （P〈0.05）. Conclusion Pitavastatin promotes the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation possibly by inhibiting inflammatory response and reducing left atrial remodeling, and its effect may be related to lipid regulation.